See more : Avenue Supermarts Limited (DMART.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Futura Medical plc (FAMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Futura Medical plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aeon Hokkaido Corporation (7512.T) Income Statement Analysis – Financial Results
- Cascades Inc. (CAS.TO) Income Statement Analysis – Financial Results
- BlackRock TCP Capital Corp. (TCPC) Income Statement Analysis – Financial Results
- Forward Pharma A/S (FWPAY) Income Statement Analysis – Financial Results
- Gresham House plc (GHE.L) Income Statement Analysis – Financial Results
Futura Medical plc (FAMDF)
About Futura Medical plc
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.10M | 0.00 | 0.00 | 0.00 | 31.78K | 0.00 | 362.73K | 170.36K | 29.48K | 43.93K | 370.90K | 75.00K | 158.00K | 125.00K | 50.00K | 150.00K | 15.00K | 0.00 | 2.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.33M | 24.73K | 19.81K | 25.01K | 0.00 | 19.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.77M | -24.73K | -19.81K | -25.01K | 31.78K | -19.85K | 362.73K | 170.36K | 29.48K | 43.93K | 370.90K | 75.00K | 158.00K | 125.00K | 50.00K | 150.00K | 15.00K | 0.00 | 2.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 57.22% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.05M | 4.13M | 3.77M | 1.93M | 10.05M | 6.04M | 4.10M | 3.51M | 4.78M | 2.37M | 1.98M | 1.44M | 1.00K | 762.00K | 810.00K | 1.40M | 1.52M | 1.08M | 1.55M | 960.00K | 627.00K | 811.00K | 683.00K | 207.00K |
| General & Administrative | 6.69M | 2.74M | 2.09M | 1.00M | 1.14M | 1.23M | 1.12M | 1.21M | 1.37M | 1.21M | 926.12K | 1.10M | 2.19M | 632.00K | 721.00K | 910.00K | 1.12M | 935.00K | 721.00K | 711.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.69M | 2.74M | 2.09M | 1.00M | 1.14M | 1.23M | 1.12M | 1.21M | 1.37M | 1.21M | 926.12K | 1.10M | 2.19M | 632.00K | 721.00K | 910.00K | 1.12M | 935.00K | 721.00K | 711.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.82K | -4.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -47.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.74M | 6.87M | 5.87M | 2.93M | 11.20M | 7.27M | 5.22M | 4.72M | 6.15M | 3.57M | 2.90M | 2.53M | 2.26M | 1.46M | 1.58M | 2.32M | 2.63M | 2.11M | 2.36M | 1.70M | 1.51M | 1.30M | 1.34M | 392.00K |
| Cost & Expenses | 10.06M | 6.87M | 5.87M | 2.93M | 11.20M | 7.27M | 5.22M | 4.72M | 6.15M | 3.57M | 2.90M | 2.53M | 2.26M | 1.46M | 1.58M | 2.32M | 2.63M | 2.11M | 2.36M | 1.70M | 1.51M | 1.30M | 1.34M | 392.00K |
| Interest Income | 71.80K | 0.00 | 0.00 | 924.00 | 22.28K | 27.58K | 19.32K | 14.71K | 38.33K | 48.26K | 9.53K | 18.49K | 24.00K | 19.00K | 14.00K | 97.00K | 161.00K | 136.00K | 133.00K | 177.00K | 48.00K | 60.00K | 22.00K | 6.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K | 29.00K | 16.00K |
| Depreciation & Amortization | 130.27K | 24.73K | 19.81K | 25.01K | 20.70K | 19.85K | 13.43K | 6.25K | 6.96K | 4.53K | 3.78K | 2.18K | 4.00K | 8.00K | 11.00K | 16.00K | 15.00K | 11.00K | 13.00K | 16.00K | 13.00K | 14.00K | 9.00K | 1.00K |
| EBITDA | -6.83M | -6.85M | -5.85M | -2.90M | -11.14M | -7.25M | -4.84M | -4.55M | -6.11M | -3.52M | -2.53M | -2.45M | -2.09M | -1.33M | -1.52M | -2.16M | -2.61M | -1.96M | -2.34M | -1.57M | -1.45M | -1.22M | -1.31M | -385.00K |
| EBITDA Ratio | -220.37% | 0.00% | 0.00% | 0.00% | -35,065.34% | 0.00% | -1,335.03% | -2,669.51% | -20,728.20% | -8,018.17% | -681.52% | -3,271.66% | -1,310.76% | -1,047.20% | -3,002.00% | -1,374.67% | -16,320.00% | 0.00% | -110,500.00% | -1,060.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.96M | -6.87M | -5.87M | -2.93M | -11.16M | -7.27M | -4.86M | -4.55M | -6.12M | -3.53M | -2.53M | -2.46M | -2.10M | -1.34M | -1.53M | -2.18M | -2.62M | -2.11M | -2.36M | -1.58M | -1.51M | -1.30M | -1.34M | -392.00K |
| Operating Income Ratio | -224.57% | 0.00% | 0.00% | 0.00% | -35,130.49% | 0.00% | -1,338.73% | -2,673.17% | -20,751.81% | -8,028.47% | -682.54% | -3,274.57% | -1,328.48% | -1,068.80% | -3,052.00% | -1,450.00% | -17,493.33% | 0.00% | -117,800.00% | -1,212.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 71.80K | 0.00 | 0.00 | 924.00 | 22.28K | 27.58K | 19.32K | 14.71K | 38.33K | 48.26K | 9.53K | 18.49K | 24.21K | 19.00K | 14.00K | 97.00K | 161.00K | 136.00K | 134.00K | 177.00K | 47.00K | 59.00K | -7.00K | -10.00K |
| Income Before Tax | -6.89M | -6.87M | -5.87M | -2.93M | -11.14M | -7.24M | -4.84M | -4.54M | -6.08M | -3.48M | -2.52M | -2.44M | -2.08M | -1.32M | -1.51M | -2.08M | -2.46M | -1.97M | -2.22M | -1.40M | -1.46M | -1.24M | -1.35M | -402.00K |
| Income Before Tax Ratio | -222.25% | 0.00% | 0.00% | 0.00% | -35,060.37% | 0.00% | -1,333.41% | -2,664.54% | -20,621.79% | -7,918.62% | -679.97% | -3,249.92% | -1,313.29% | -1,053.60% | -3,024.00% | -1,385.33% | -16,420.00% | 0.00% | -111,150.00% | -1,076.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -379.07K | -1.02M | -908.60K | -519.09K | -2.22M | -1.36M | -936.34K | -842.25K | -997.04K | -480.69K | -313.68K | -260.79K | -260.00K | -226.00K | -119.00K | -143.00K | -209.00K | -196.00K | -287.00K | -170.00K | -101.00K | -152.00K | -100.00K | -30.00K |
| Net Income | -6.51M | -5.85M | -4.96M | -2.41M | -8.92M | -5.88M | -3.90M | -3.70M | -5.08M | -3.00M | -2.21M | -2.18M | -1.82M | -1.09M | -1.39M | -1.94M | -2.25M | -1.78M | -1.94M | -1.23M | -1.36M | -1.09M | -1.25M | -372.00K |
| Net Income Ratio | -210.03% | 0.00% | 0.00% | 0.00% | -28,067.50% | 0.00% | -1,075.27% | -2,170.15% | -17,239.25% | -6,824.38% | -595.40% | -2,902.20% | -1,148.73% | -872.80% | -2,786.00% | -1,290.00% | -15,026.67% | 0.00% | -96,800.00% | -945.38% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 | -0.01 |
| Weighted Avg Shares Out | 294.91M | 287.48M | 271.05M | 243.72M | 204.66M | 131.94M | 121.32M | 101.93M | 99.59M | 89.96M | 78.04M | 75.17M | 72.18M | 67.95M | 62.58M | 57.95M | 55.92M | 52.60M | 48.96M | 48.34M | 43.15M | 40.96M | 30.88M | 27.36M |
| Weighted Avg Shares Out (Dil) | 294.91M | 287.48M | 271.05M | 243.72M | 204.66M | 131.94M | 121.32M | 101.93M | 99.59M | 89.96M | 78.04M | 75.17M | 72.18M | 67.95M | 62.58M | 57.95M | 55.92M | 52.60M | 48.96M | 48.34M | 45.29M | 40.96M | 30.88M | 27.36M |
Futura Medical completes work ahead of FDA submission for ED gel
Futura Medical PLC (AIM:FUM, OTC:FAMDF) said it had now completed all the work required to make its submission for US regulatory sign-off for MED3000, its fast-acting erectile dysfunction gel. It expects to receive marketing approval towards the end of the...
Futura Medical on track to disclose the results of FM71 study in early September
Futura Medical PLC (AIM:FUM, OTC:FAMDF) will tell shareholders at today's annual general meeting (AGM) that 2021 was “a year of transformational progress”. A statement issued ahead of the AGM Futura listed highlights of the year, among them MED3000 receiving UKCA...
Source: https://incomestatements.info
Category: Stock Reports